In This Article:
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.
Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.
The 10 therapeutics stocks we track reported a satisfactory Q4. As a group, revenues beat analysts’ consensus estimates by 2.6%.
While some therapeutics stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 1.2% since the latest earnings results.
Best Q4: BioMarin Pharmaceutical (NASDAQ:BMRN)
Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children.
BioMarin Pharmaceutical reported revenues of $747.3 million, up 15.6% year on year. This print exceeded analysts’ expectations by 4.8%. Overall, it was a stunning quarter for the company with an impressive beat of analysts’ EPS estimates.
"Our operational transformation and strong financial execution in 2024 is the first step in BioMarin's ambitious multiyear growth plan," said Alexander Hardy, President and Chief Executive Officer of BioMarin.
BioMarin Pharmaceutical pulled off the highest full-year guidance raise of the whole group. The stock is up 7.5% since reporting and currently trades at $70.61.
Is now the time to buy BioMarin Pharmaceutical? Access our full analysis of the earnings results here, it’s free.
Gilead Sciences (NASDAQ:GILD)
From its groundbreaking work in developing the first single-tablet regimens for HIV treatment, Gilead Sciences (NASDAQ:GILD) develops and markets innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, and cancer.
Gilead Sciences reported revenues of $7.57 billion, up 6.4% year on year, outperforming analysts’ expectations by 6.3%. The business had a very strong quarter with an impressive beat of analysts’ full-year EPS guidance estimates.
Gilead Sciences delivered the biggest analyst estimates beat among its peers. The market seems happy with the results as the stock is up 9.8% since reporting. It currently trades at $105.58.